КСКалдыгуль Кабаковна Смагулова

Калдыгуль Кабаковна Смагулова

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Калдыгуль Кабаковна Смагулова has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    2nd Saint Petersburg International Consensus on the Diagnosis and Treatment of Breast Cancer «White Nights 2025»

    by Владимир Федорович Семиглазов, Петр Владимирович Криворотько, Татьяна Юрьевна Семиглазова, Елена Владимировна Артамонова, Светлана Геннадьевна Багрова, Елена Михайловна Бит-Сава, Алла Александровна Божок, Лариса Владимировна Болотина, Любовь Юрьевна Владимирова, Вера Андреевна Горбунова, et al.

    В данной публикации представлены результаты II Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2025», который продолжает традицию углубленного обсуждения актуальных и спорных вопросов, возникающих в клинической практике. Под председательством члена-корреспондента РАН, профессора Владимира Федоровича Семиглазова в консенсусе приняли участие ведущие эксперты в области диагностики, хирургии, лучевой терапии и системного лечения рака молочной железы. Эксперты обсудили и проголосовали по 60 ключевым вопросам, касающимся как ранних стадий заболевания, так и метастатического рака молочной железы. Результаты консенсуса обеспечат необходимую основу для дальнейшего совершенствования клинической практики и разработки рекомендаций, направленных на улучшение лечения и качества жизни пациентов с данным заболеванием. Проведение III Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2026» запланировано на 4 июля 2026 г.

  • KRAS GENE MUTATION STATUS IN COLORECTAL CANCER IN THE REPUBLIC OF KAZAKHSTAN: RESULTS OF THE FIRST MULTICENTRE RETROSPECTIVE STUDY

    by K. Smagulova, S. Khaydarov, D. Kaidarova, E. Makimbetov, I. Turkpenova

    Colorectal cancer ranks third worldwide in terms of the number of new cases and second in terms of cancer-related mortality. KRAS gene status determines the eligibility for anti-EGFR therapy; however, prior to this study, data on Kazakh patients had only been collected in individual clinics and had not been collated. The aim was to determine the frequency and spectrum of KRAS mutations in patients with verified colorectal cancer across several oncology centres in Kazakhstan and to assess their association with clinical and epidemiological parameters. This retrospective, multicentre study included 332 patients with morphologically confirmed stage IIIV colorectal cancer. Mutation status was determined using real-time allele-specific polymerase chain reaction on FFPE tissue blocks. The Pearson’s χ2 test (Fisher’s exact test for small expected frequencies) was used to compare groups; the strength of association was assessed using the odds ratio with a 95% confidence interval; logistic regression was applied for multivariate analysis. A KRAS mutation was detected in 149 patients (44.9 ± 2.7%), whilst the wild-type was found in 183 (55.1 ± 2.7%). The majority of mutations (80.5%) occurred at codon 12, with the most common variants being G12D (32.2%), G12V (24.8%) and G13D (19.5%). No statistically significant association was found between mutation status and gender (p=0.46), ethnicity (p=0.30), age (p=0.29) or tumour site (p = 0.45-0.74 depending on the grouping); in the multivariate model, none of these factors proved to be an independent predictor. The frequency of KRAS mutations in the Kazakh cohort (44.9%) falls within the global range of 40-45%, and the pattern of variants mirrors the findings of major international studies. The results confirm the need for routine extended RAS testing in cancer centres in Kazakhstan Колоректальный рак занимает третье место в мире по числу новых случаев и второе – по смертности от онкологических заболеваний. Статус гена KRAS определяет возможность назначения антиEGFR-терапии, однако до настоящей работы данные по казахстанским пациентам собирались только в отдельных клиниках и не обобщались. Цель – определить частоту и спектр мутаций KRAS у пациентов с верифицированным колоректальным раком на базе нескольких онкологических центров Казахстана и оценить их связь с клинико-эпидемиологическими параметрами. В ретроспективное многоцентровое исследование включено 332 пациента с морфологически подтверждённым колоректальным раком II-IV стадии. Мутационный статус определяли методом аллель-специфической полимеразной цепной реакции. в реальном времени на материале FFPE-блоков. Для сравнения групп использовали критерий χ2 Пирсона (точный критерий Фишера при малых ожидаемых частотах), силу связи оценивали через отношение шансов с 95% доверительного интервала; для многофакторного анализа применяли логистическую регрессию. Мутация KRAS обнаружена у 149 пациентов (44,9 ± 2,7%), дикий тип – у 183 (55,1 ± 2,7%). Основная часть мутаций (80,5%) приходилась на кодон 12, лидировали варианты G12D (32,2%), G12V (24,8%) и G13D (19,5%). Статистически значимой связи мутационного статуса с полом (p=0,46), этнической принадлежностью (p = 0,30), возрастом (p = 0,29) и локализацией опухоли (p = 0,45-0,74 в зависимости от группировки) не выявлено; в многофакторной модели ни один из этих факторов не оказался независимым предиктором. Частота KRAS-мутаций в казахстанской когорте (44,9%) укладывается в мировой диапазон 40-45%, а структура спектра вариантов повторяет данные крупных международных исследований. Результаты подтверждают необходимость рутинного расширенного RAS-тестирования в онкологических центрах Казахстана Колоректалдык рак дүйнө жүзүндө жаңы учурлардын саны боюнча үчүнчү, ал эми онкологиялык оорулардан өлүм көрсөткүчү боюнча экинчи орунда турат. KRAS генинин статусу антиEGFR терапиясын дайындоо мүмкүнчүлүгүн аныктайт, бирок ушул изилдөөгө чейин казакстандык бейтаптар боюнча маалыматтар айрым клиникаларда гана топтолуп, жалпыланган эмес. Изилдөөнүн максаты – Казакстандын бир нече онкологиялык борборлорунун базасында колоректалдык рагы тастыкталган бейтаптардагы KRAS...

  • Open Access

    EFFICACY OF ERYTHROPOIETIN IN THE CORRECTION OF ANEMIA IN ONCOLOGY PATIENTS UNDERGOING CHEMOTHERAPY

    by D.U. Shayakhmetova, D.R. Kaidarova, K.K. Smagulova, N. Toktakhan, Zh.M. Amankulov, N.Z. Toktahan

    Relevance: Anemia is a common complication in oncology patients, reducing their quality of life and potentially decreasing the effectiveness of antitumor therapy. Its prevalence among patients with solid tumors reaches 40%, and during chemotherapy, it increases to 54%. The deterioration in patients’ condition is associated with chemotherapy-induced myelosuppression, making anemia correction a crucial task. The primary pharmacological method for correction is using erythropoietins, which stimulate the proliferation of erythroid progenitor cells.The study aimed to evaluate the effectiveness and safety of erythropoietin in correcting anemia in oncology patients receiving chemotherapy, focusing on improving treatment outcomes by correcting hematological parameters in real clinical practice.Methods: This prospective, non-interventional study included 133 patients from two clinical centers in Kazakhstan. Inclusion criteria: age ≥18 years, histologically confirmed solid tumor, anemia (Hb ≤100 g/L), and ongoing chemotherapy. The sample included 100 (75.2%) women and 33 (24.8%) men, with a median age of 60 years (52.0-67.5). The drug was administered 3 to 5 times in 78.2% of patients and 1 to 2 times in 21.8%. Statistical analysis was performed using the Friedman and Wilcoxon criteria, with a significance level of p<0.05.Results: Data from 133 patients were analyzed. An increase in hemoglobin and erythrocyte levels was observed in 65.4-78.2% of patients. In the first and third months, hemoglobin levels increased by 0.6 g/L (p<0.001), and erythrocyte levels increased by 0.2-0.3×10¹²/L (p<0.001). 33.1% of patients received the drug five or more times. No serious adverse events were recorded.Conclusion: Erythropoietin demonstrated a statistically significant improvement in clinical parameters, confirming its effectiveness and safety in correcting anemia in oncology patients receiving chemotherapy. This contributes to an improved quality of life and better treatment outcomes.

  • Open Access

    EFFICACY OF ERYTHROPOIETIN IN THE CORRECTION OF ANEMIA IN ONCOLOGY PATIENTS UNDERGOING CHEMOTHERAPY

    by D. Shayakhmetova, D. Kaidarova, К.к. Смагулова, N. Toktahan, Ж.м. Аманкулов, Д.у. Шаяхметова, Д.р. Кайдарова, Н.з. Тоқтахан

    Relevance: Anemia is a common complication in oncology patients, reducing their quality of life and potentially decreasing the effectiveness of antitumor therapy. Its prevalence among patients with solid tumors reaches 40%, and during chemotherapy, it increases to 54%. The deterioration in patients’ condition is associated with chemotherapy-induced myelosuppression, making anemia correction a crucial task. The primary pharmacological method for correction is using erythropoietins, which stimulate the proliferation of erythroid progenitor cells. The study aimed to evaluate the effectiveness and safety of erythropoietin in correcting anemia in oncology patients receiving chemotherapy, focusing on improving treatment outcomes by correcting hematological parameters in real clinical practice. Methods: This prospective, non-interventional study included 133 patients from two clinical centers in Kazakhstan. Inclusion criteria: age ≥18 years, histologically confirmed solid tumor, anemia (Hb ≤100 g/L), and ongoing chemotherapy. The study population comprised 100 (75.2%) women and 33 (24.8%) men, with a median age of 60 years (52.0-67.5). The drug was administered 3 to 5 times in 78.2% of patients and 1 to 2 times in 21.8% of patients. Statistical analysis was performed using the Friedman and Wilcoxon criteria, with a significance level of p<0.05. Results: Data from 133 patients were analyzed. An increase in hemoglobin and erythrocyte levels was observed in 65.4-78.2% of patients. In the first and third months, hemoglobin levels increased by 0.6 g/L (p<0.001), and erythrocyte levels increased by 0.2-0.3×10¹²/L (p<0.001). 33.1% of patients received the drug five or more times. No serious adverse events were recorded. Онкогематология. – 2020. – Т. 15, № 2. – С. 45-52 [Romanenko N.A., Alborov A.E’., Bessmel’cev S.S., Shilova E.R., Voloshin S.V., Chechetkin A.V. Patogeneticheskaya i zamestitel’naya korrekciya anemii u pacientov so zlokachestvennymi novoobrazovaniyami // Onkogematologiya. – 2020. – T. 15, № 2. – S. 45-52 (in Russ.)]. https://cyberleninka.ru/article/n/patogeneticheskayai-zamestitelnaya-korrektsiya-anemii-u-patsientov-sozlokachestvennymi-novoobrazovaniyami ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ Онкология и Радиология Казахстана, №1 (75) 2025 69 Conclusion: Erythropoietin demonstrated a statistically significant improvement in clinical parameters, confirming its effectiveness and safety in correcting anemia in oncology patients receiving chemotherapy. This contributes to an improved quality of life and better treatment outcomes.

  • Open Access

    I St. Petersburg International Consensus on the Diagnosis and Treatment of Breast Cancer «White Nights 2024»

    by Владимир Федорович Семиглазов, Петр Владимирович Криворотько, Татьяна Юрьевна Семиглазова, Елена Владимировна Артамонова, Анна Сергеевна Артемьева, Светлана Геннадьевна Багрова, Лариса Владимировна Болотина, Елена Михайловна Бит-Сава, Алла Александровна Божок, Любовь Юрьевна Владимирова, et al.

    В статье представлены результаты голосования I Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2024», посвященного наиболее актуальным и спорным вопросам диагностики, хирургической тактики, лучевой терапии и системного лечения данной категории пациентов. Под председательством член-корреспондента РАН, профессора Владимира Федоровича Семиглазова в международном консенсусе приняли участие 38 экспертов в области диагностики и лечения рака молочной железы (РМЖ), проголосовавших в ходе прямого эфира по 32 вопросам, разделенным на блоки раннего и метастатического РМЖ. Проведение II Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2025» запланировано со 2 по 5 июля 2025 года.


  • CURRENT DRUG THERAPY OPTIONS FOR DISSEMINATED HER2-POSITIVE BREAST CANCER AT THE KAZAKH SCIENTIFIC RESEARCH INSTITUTE OF ONCOLOGY AND RADIOLOGY: A CLINICAL CASE

    by D. Kaidarova, M. Dmitrenko, K. Smagulova, S. Kaldarbekov

    Relevance: Distant outcomes of treatment for Her2neu-positive metastatic breast cancer are improving due to access to innovative drug therapies. The study aimed to demonstrate the initial experience of treating a patient with progressive disseminated hormone receptor-positive breast cancer expressing HER2 (3+) and nearly exhausted options for anti-tumor drug therapy using trastuzumab deruxtecan. Methods: The paper describes a clinical case of a female patient born in 1977 who was diagnosed with Stage IV breast cancer (T1N1M1), invasive ductal carcinoma, and treated at the Kazakh Institute of Oncology and Radiology (Almaty, Kazakhstan). Immunohistochemical luminal subtype “B” with Her2neu (3+) expression. Metastatic involvement of skeletal bones with pain syndrome, lungs, liver, axillary, parasternal, and para-mediastinal lymph nodes. Since June 2023, monoclonal antibody conjugate trastuzumab deruxtecan therapy was initiated. The efficacy of fifth-line therapy was assessed using RECIST 1.1 before and during treatment. According to RECIST 1.1., target lesions included a conglomerate of hyperplastic axillary lymph nodes on the right, measuring 1.6 cm, parasternal lymph node 1.6 cm, a lesion in the parenchyma of the lower lobe of the left lung 1.3 cm, lesions (n=2) in the parenchyma of segment 2 of the left liver lobe 1.8 cm and 3.6 cm. Non-target lesion: hyperplastic para-mediastinal lymph nodes SLD 9.9 cm. Results: Pain syndrome was completely relieved after treatment. According to RECIST 1.1. in April 2024, after 11 courses of therapy, target lesions showed size reduction: conglomerate of hyperplastic axillary lymph nodes on the right decreased to 1.0 cm, lesion in the parenchyma of the lower lobe of the left lung increased to 2.7 cm, parasternal lymph node was not visualized, lesions (n=2) in the parenchyma of segment 2 of the left liver lobe measured 1.6 cm and 2.7 cm. Non-target lesion: hyperplastic para-mediastinal lymph nodes were not visualized. Conclusion: According to the clinical study data (DESTINY-Breast02), applying antibody-drug conjugate (ADC) demonstrates better objective response and progression-free survival time in patients previously treated with trastuzumab and taxanes.

  • GENOME-WIDE ASSOCIATION STUDY IN BREAST CANCER: A LITERATURE REVIEW

    by D. Kaidarova, N. Omarbayeva, D. Omarov, A. Abdrakhmanova, K. Smagulova, T. Goncharova

    Relevance: Breast cancer (BC) is one of the major health problems in the Republic of Kazakhstan. Genome-wide association studies (GWAS) are used to identify genetic factors contributing to breast cancer development in Kazakhstan and worldwide. The GWAS method consistently helps to find associations between certain single nucleotide polymorphisms (SNPs) in the genome and the development of pathological conditions, including breast cancer, by identifying more than 170 genomic sites. In addition to searching for loci associated with BC, these studies have expanded our understanding of BC heritability using SNPs located in regulatory areas and identifying DNA variants associated with drug metabolism for treatment personalization purposes. The study aimed to highlight the key concepts of modern methods in genetics based on GWAS. Methods: A literature search in PubMed, Scopus, GWAS Catalog, Cochrane Database of Systematic Reviews, etc., was performed to select and analyze relevant information. Results: The article describes significant GWAS studies in the field of breast cancer, describes certain genes associated with the development of the disease, identifies shortcomings, and identifies further strategies for the development of GWAS in the Republic of Kazakhstan. Conclusion: The results of this study have improved our understanding of the biological mechanisms that contribute to breast cancer risk and may ultimately lead to the development of new targeted therapies for the disease.


  • GENOME-WIDE ASSOCIATION STUDY IN BREAST CANCER: A LITERATURE REVIEW

    by D. Kaidarova, N. Omarbayeva, D. Omarov, A. Abdrakhmanova, K. Smagulova, T. Goncharova

    Relevance: Breast cancer (BC) is one of the major health problems in the Republic of Kazakhstan. Genome-wide association studies (GWAS) are used to identify genetic factors contributing to breast cancer development in Kazakhstan and worldwide. The GWAS method consistently helps to find associations between certain single nucleotide polymorphisms (SNPs) in the genome and the development of pathological conditions, including breast cancer, by identifying more than 170 genomic sites. In addition to searching for loci associated with BC, these studies have expanded our understanding of BC heritability using SNPs located in regulatory areas and identifying DNA variants associated with drug metabolism for treatment personalization purposes. The study aimed to highlight the key concepts of modern methods in genetics based on GWAS. Methods: A literature search in PubMed, Scopus, GWAS Catalog, Cochrane Database of Systematic Reviews, etc., was performed to select and analyze relevant information Results: The article describes significant GWAS studies in the field of breast cancer, describes certain genes associated with the development of the disease, identifies shortcomings, and identifies further strategies for the development of GWAS in the Republic of Kazakhstan Conclusion: The results of this study have improved our understanding of the biological mechanisms that contribute to breast cancer risk and may ultimately lead to the development of new targeted therapies for the disease


  • CHECKPOINT INHIBITORS IN THE TREATMENT OF LOCALLY ADVANCED AND METASTATIC GASTRIC CANCER: A LITERATURE REVIEW

    by M. Dmitrenko, K. Smagulova, R. Abdrahmanov, R. Raskaliev, I. Turkpenova, E. Medetbekova, S. Kaldarbekov, A. Kuanysh, Z. Kenzhebayeva, D. Shayakhmetova, et al.

    Relevance: Stomach cancer (SC) is one of the most common malignant neoplasms and ranks fifth in cancer incidence worldwide. The only curative approach to localized SC is radical surgery with or without prior chemotherapy. But chemotherapy is the main treatment method for metastatic or locally advanced SC. In the later stages of SC, there is high resistance to chemotherapy; therefore, there is a need to find modern treatment approaches. Particular attention is paid to therapy for metastatic/locally advanced SC. The study aimed to describe the possibilities of using immune checkpoint inhibitors (CPI) to treat metastatic or locally advanced SC. Methods: The data from modern literary sources of recent years were studied using specialized scientific search engines: Scopus, PubMed, Google Scholar, and Web of Science for the possibility of promising application of various immunotherapeutic approaches in treating metastatic or locally advanced SC. Results: The article describes modern methods of treatment of metastatic or locally advanced SC using CPIs, including PD-1, PD-L1, and CTLA-4, demonstrates the mechanisms of immunological surveillance, characteristics of PD-1, PD-L1, CTLA-4 and their significance in suppressing the T-cell response. The effectiveness of using CPIs, particularly PD-1, PD-L1, and CTLA-4, has been established in the first and subsequent lines of therapy. Conclusion: CPIs are a recent finding in antitumor therapy. Frequent resistance of SC to chemotherapy urges the use of CPIs to treat advanced SC

  • MALE BREAST CANCER TREATMENT: A CLINICAL CASE*

    by D. Kaidarova, A. Abdrakhmanova, M. Dmitrenko, A. Baizhigitov, N. Chichua, K. Smagulova, R. Abdrakhmanov, S. Kaldarbekov

    Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing. This paper demonstrate the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery. Methods: The article describes a clinical case of a male patient diagnosed with “Cancer of the right breast St III (T4NxM0), edematous-infiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses. Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3. Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II. Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years. * clinical case, male breast cancer (BC), luminal subtype B without Her2neu expression, mastectomy, therapeutic pathomorphism, radiation therapy, endocrine therapy.